UNSPSC 42221909: Chemotherapy dosage regulators

In this classification, this commodity that indicates a product that is a regulator for chemotherapy dosages used in a medical setting Most nations, for tariff and trade purposes, schedule these products under HS 901890.

UNSPSC 42221909 Chemotherapy dosage regulators is a Commodity code that, based on recent state and local solicitation activity, encompasses pharmaceutical and medical supply procurement including emergency-response medications and harm-reduction systems. State and local governments sourcing under this code include county health departments and community health agencies. The work involves procurement of FDA-regulated medical products for public health initiatives, with vendors required to meet federal compliance standards including E-Verify, drug-free workplace certification, and in some cases FEMA-funded project requirements such as adherence to the Clean Air Act and Federal Water Pollution Control Act. Contracts typically span two years with optional renewal periods, and vendors must carry workers' compensation, commercial general liability, and professional liability insurance. Delivery and logistics are vendor-responsible, with quarterly or regular delivery schedules to county health facilities.

Seminole County, Florida represents the most recent documented activity under this code. The county issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The competitive bid process required electronic submission through the county's e-Procurement Portal by July 26, 2023, at 2:00 pm, and included a three-month probationary period allowing termination with or without cause. While the source documents this single solicitation, recent state and local opportunities under the code are limited; the mismatch between the code's nominal scope (chemotherapy dosage regulators) and the actual procurement (naloxone and drug deactivation systems) suggests this code may see sparse or mislabeled activity in state and local markets, warranting verification of whether opportunities are being tagged accurately or whether the code itself sees material volume in this sector.